Procter & Gamble Health Intrinsic Value
PGHL Valuation Methods Summary
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹3889.60 | ₹3111.68 - ₹4667.52 | -20.4% | EPS: ₹176.80, Sector P/E: 22x |
| Book Value Method | asset | ₹977.50 | ₹879.75 - ₹1075.25 | -80.0% | Book Value/Share: ₹315.88, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹1605.88 | ₹1445.29 - ₹1766.47 | -67.1% | Revenue/Share: ₹802.94, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹2458.82 | ₹2212.94 - ₹2704.70 | -49.7% | EBITDA: ₹418.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹1955.00 | ₹1564.00 - ₹2346.00 | -60.0% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹1571.50 | ₹1414.35 - ₹1728.65 | -67.8% | EPS Growth: 11.1%, Fair P/E: 8.9x |
| Growth Adjusted P/E | growth | ₹2716.75 | ₹2445.08 - ₹2988.43 | -44.4% | Revenue Growth: 4.9%, Adj P/E: 15.4x |
| ROE Based Valuation | profitability | ₹2767.06 | ₹2490.35 - ₹3043.77 | -43.4% | ROE: 54.7%, P/E Multiple: 16x |
| Graham Defensive Method | conservative | ₹1466.25 | ₹1319.62 - ₹1612.88 | -70.0% | EPS: ₹176.80, BVPS: ₹315.88 |
Want to compare with current market value? Check PGHL share price latest .
Valuation Comparison Chart
PGHL Intrinsic Value Analysis
What is the intrinsic value of PGHL?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Procter & Gamble Health (PGHL) is ₹1955.00 (median value). With the current market price of ₹4887.50, this represents a -60.0% variance from our estimated fair value.
The valuation range spans from ₹977.50 to ₹3889.60, indicating ₹977.50 - ₹3889.60.
Is PGHL undervalued or overvalued?
Based on our multi-method analysis, Procter & Gamble Health (PGHL) appears to be trading above calculated value by approximately 60.0%.
Financial Health Analysis
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Current Ratio | 12.52 | Industry Standard: 2.0+ | Above 2.0 | Measures short-term liquidity capacity |
| Return on Equity | 54.7% | Industry Standard: 15%+ | Above 15% | Measures shareholder return efficiency |
| Operating Margin | 30.0% | Industry Standard: 20%+ | Above 20% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.72x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
Related Pages for Procter & Gamble Health
Additional stock information and data for PGHL
Cash Flow Quality Analysis
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹169 Cr | ₹169 Cr | Positive Free Cash Flow | 8/10 |
| March 2024 | ₹228 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹236 Cr | ₹225 Cr | Positive Free Cash Flow | 8/10 |
| March 2022 | ₹170 Cr | ₹157 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹247 Cr | ₹231 Cr | Positive Free Cash Flow | 8/10 |